Drug
Skx 16
Skx 16: highest development phase Phase 2, developed by SATO Pharmaceutical Co., Ltd.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- SATO Pharmaceutical Co., Ltd.
Trials
| Drug | Phase | Indication |
|---|---|---|
| SKX-16 (Luliconazole 10% Solution) NCT07929844 | Phase 2 | Onychomycosis of Toenails |
Latest
No recent events.
Follow Skx 16 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.